Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate

Medical Oncology

Volumn 28, Issue 2, 2011, Pages 401-408

  Petrelli, Fausto ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; HER2 neu; Prognosis; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; LYMPH NODE; NEU GENE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; GENES, ERBB-2; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC;

EID: 79960302454     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9460-0     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
2. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al., editors. AJCC cancer staging handbook: TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002.
3. http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf.
4. AN Mirza NQ Mirza G Vlastos SE Singletary 2002 Prognostic factors in node-negative breast cancer Ann Surg 235 1 10 26 11753038 10.1097/00000658- 200201000-00003 (Pubitemid 34062395)
5. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
6. P Rudolph H Olsson G Bonatz V Ratjen H Bolte B Baldetorp M Fernö R Parwaresch P Alm 1999 Correlation between p53, c-erbB-2, and topoisomerase IIa expression, DNA ploidy, hormonal receptor status and proliferation in 356 node negative breast carcinomas: prognostic implications J Pathol 187 207 216 10365096 10.1002/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U 1:CAS:528:DyaK1MXht1Cnu7w%3D (Pubitemid 29037050)
7. G Gasparini WJ Gullick S Maluta P Dalla Palma O Caffo E Leonardi P Boracchi F Pozza NR Lemoine P Bevilacqua 1994 c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma-an immunocytochemical study Eur J Cancer 30A 16 22 7908213 10.1016/S0959-8049(05)80010-3 1:STN:280: DyaK2c7ptVKmsw%3D%3D (Pubitemid 24058081)
8. N Quenel J Wafflart F Bonichon I de Mascarel M Trojani M Durand A Avril JM Coindre 1995 The prognostic value of c-erbB-2 in primary breast carcinomas: a study on 942 cases Breast Cancer Res Treat 35 283 291 7579499 10.1007/BF00665980 1:STN:280:DyaK28%2FntVaruw%3D%3D
9. BA Gusterson RD Gelber A Goldhirsch KN Price J Save-Soderborgh tR Anbazhagan J Styles C-M Rudenstam R Golouh R Reed F Martinez-Tello A Tiltman, et al. 1992 Prognostic importance of c-erbB-2 expression in breast cancer J Clin Oncol 10 1049 1056 1351538 1:STN:280:DyaK38zgtVCjtA%3D%3D
10. S Bianchi M Paglierani G Zampi G Cardona L Cataliotti R Bonardi S Ciatto 1993 Prognostic significance of c-erbB-2 expression in node-negative breast cancer Br J Cancer 67 625 629 8094977 10.1038/bjc.1993.114 1:STN:280: DyaK3s7ns1Oisg%3D%3D (Pubitemid 23077664)
11. S Tsutsui S Ohno S Murakami Y Hachitanda S Oda 2002 Prognostic value of c-ErbB2 expression in breast cancer J Surg Oncol 72 216 223 10.1002/jso.10079 (Pubitemid 34259814)
12. MF Press L Bernstein PA Thomas LF Meisner JY Zhou Y Ma G Hung RA Robinson C Harris A El-Naggar DJ Slamon RN Phillips, et al. 1997 HER2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 2894 2904 9256133 1:STN:280:DyaK2szpvVajug%3D%3D (Pubitemid 27330017)
13. Choi YH, Ahn JH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH, Kim WK. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu over-expression is an important predictive marker of poor prognosis. Ann Oncol. 2009 [Epub ahead of print].
14. De Boer RH, Chan A. Clinical outcomes of patients with T1N0 breast cancers: how important are biological risk factors? Program and abstracts of the 31st annual San Antonio breast cancer symposium, 10-14 Dec 2008, San Antonio, Texas. Abstract 2078.
15. RD Mass MF Press S Anderson MA Cobleigh CL Vogel N Dybdal G Leiberman DJ Slamon 2005 Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 6 3 240 246 16137435 10.3816/CBC.2005.n.026 (Pubitemid 47050800)
16. M Schmidt B Lewark N Kohlschmidt C Glawatz E Steiner B Tanner H Pilch W Weikel H Kölbl HA Lehr 2005 Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing Breast Cancer Res 7 R256 R266 15743506 10.1186/bcr991 1:CAS:528:DC%2BD2MXhslyjtbw%3D
17. IL Andrulis SB Bull ME Blackstein D Sutherland C Mak S Sidlofsky KP Pritzker RW Hartwick W Hanna L Lickley R Wilkinson A Qizilbash U Ambus M Lipa H Weizel A Katz M Baida S Mariz G Stoik P Dacamara D Strongitharm W Geddie D McCready 1998 neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group J Clin Oncol 16 4 1340 1349 9552035 1:STN:280:DyaK1c3htFOlsw%3D%3D (Pubitemid 28175749)
18. MC Paterson KD Dietrich J Danyluk AH Paterson AW Lees N Jamil J Hanson H Jenkins BE Krause WA McBlain, et al. 1991 Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer Cancer Res 51 2 556 567 1670762 1:STN:280:DyaK3M%2FptFyksQ%3D%3D
19. H Joensuu J Isola M Lundin T Salminen K Holli V Kataja L Pylkkänen T Turpeenniemi-Hujanen K von Smitten J Lundin 2003 Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study Clin Cancer Res 9 3 923 930 12631589 1:CAS:528:DC%2BD3sXhvFKiuro%3D (Pubitemid 36323694)
20. M Colleoni N Rotmensz G Peruzzotti P Maisonneuve G Viale G Renne C Casadio P Veronesi M Intra R Torrisi A Goldhirsch 2004 Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies Ann Oncol 15 1633 1639 15520064 10.1093/annonc/ mdh434 1:STN:280:DC%2BD2crkslSksg%3D%3D (Pubitemid 39562603)
21. S Chia B Norris C Speers M Cheang B Gilks AM Gown D Huntsman IA Olivotto TO Nielsen K Gelmon 2008 Human epidermal growth factor receptor 2 over-expression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 35 5697 5704 19001334 10.1200/JCO.2007.15.8659 1:CAS:528:DC%2BD1MXotFemsw%3D%3D Epub 2008 Nov 10
22. Amar S, Ann ME, Geiger XJ, Rebecca MB, Winston T, Kyle CE, Beiyun C, Boughey JC, Edith PA. Prognosis and clinical outcome of patients with node negative ≤1 cm breast cancer. Program and abstracts of the 30th annual San Antonio breast cancer symposium, 13-16 Dec 2007, San Antonio, Texas. Abstract 6024.
23. Tovey SM, Marla S, Brown S Burton P, Canney P, Stallard S, Mallon E, Edwards J, Cooke T. Poor survival outcomes in HER2 positive breast cancer patients with low G, node negative tumours. Implications for trastuzumab. Program and abstracts of the 30th annual San Antonio breast cancer symposium, 13-16 Dec 2008, San Antonio, Texas. Abstract 702.
24. Ananthakrishnan P, Patrick RJ, Rybicki LA, Tubbs RR, Crowe JP, Budd GT. HER2 amplification does not alter outcome in small (≤1 cm) tumors. Program and abstracts of the 31st annual San Antonio breast cancer symposium, 10-14 Dec 2008, San Antonio, Texas. Abstract 6058.
25. AM Gonzalez-Angulo JK Litton KR Broglio F Meric-Bernstam R Rakkhit F Cardoso F Peintinger EO Hanrahan A Sahin M Guray D Larsimont, et al. 2009 High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27 34 5700 5706 19884543 10.1200/JCO.2009.23.2025
26. G Curigliano G Viale V Bagnardi L Fumagalli M Locatelli N Rotmensz R Ghisini M Colleoni E Munzone P Veronesi S Zurrida F Nolè A Goldhirsch 2009 Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer J Clin Oncol 27 34 5693 5699 19884553 10.1200/JCO.2009.22.0962
27. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik, et al. 2007 American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528: DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
28. CB Moeder JM Giltnane M Harigopal A Molinaro A Robinson K Gelmon D Huntsman RL Camp DL Rimm 2007 Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome J Clin Oncol 25 34 5418 5425 18048824 10.1200/JCO.2007.12. 8033 (Pubitemid 350232218)
29. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov, et al. 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
30. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
31. MJ van de Vijver YD He LJ van't Veer H Dai AA Hart DW Voskuil GJ Schreiber JL Peterse C Roberts MJ Marton M Parrish D Atsma, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 1999 2009 12490681 10.1056/NEJMoa021967 (Pubitemid 35461656)
32. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga M Kaufmann D Cameron, et al. 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36 17208639 10.1016/S0140-6736(07)60028-2 1:CAS:528:DC%2BD2sXit12itg%3D%3D (Pubitemid 46039831)
33. M Untch RD Gelber C Jackisch M Procter J Baselga R Bell D Cameron M Bari I Smith B Leyland-Jones E de Azambuja P Wermuth, et al. 2008 Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial Ann Oncol 19 1090 1096 18296421 10.1093/annonc/mdn005 1:STN:280: DC%2BD1czktlSlsA%3D%3D (Pubitemid 351796334)
34. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, Chan A, Mackey J, Liu M, Pinter T, Valero V, Falkson C et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Abstract 62 presented at the CTRC-AACR annual San Antonio breast cancer symposium, San Antonio, Texas, USA, 9-13 Dec 2009.
35. Perez EA, Suman VJ, Davidson NE, Gralow J, Kaufman PA, Ingle JN, Dakhil SR, Zujewski JA, Pisansky TM, Jenkins RB. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Abstract 80 presented at the CTRC-AACR annual San Antonio breast cancer symposium, San Antonio, Texas, USA, 9-13 Dec 2009.
36. DG Hicks RR Tubbs 2005 Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines Hum Pathol 36 3 250 261 15791569 10.1016/j.humpath.2004.11.010 1:CAS:528:DC%2BD2MXis1Grsbk%3D (Pubitemid 40404008)
37. L Harris H Fritsche R Mennel L Norton P Ravdin S Taube MR Somerfield DF Hayes RC Bast Jr 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 33 5287 5312 17954709 10.1200/JCO.2007.14.2364 1:CAS:528:DC%2BD2sXhsVKnsbzK (Pubitemid 350232263)
38. Rodrigues MJ, Albiges-Sauvin L, Stevens D, Brain E, Delaloge S, Mathieu M, Guillot E, Vincent-Salomon A, Cottu PH. Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: a joint AERIO/REMAGUS study. J Clin Oncol 2009; 27:15s, (suppl; abstr 517).
39. S Dawood K Broglio AU Buzdar GN Hortobagyi SH Giordano 2010 Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 1 92 98 19933921 10.1200/JCO.2008.19.9844 1:CAS:528:DC%2BC3cXhtF2rsr0%3D
40. GA Viani SL Afonso EJ Stefano LI De Fendi FV Soares 2007 Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 153 17686164 10.1186/1471-2407-7-153 (Pubitemid 47354734)